Join
Live feed
·
PRReleasevia Quantisnow
Senti Biosciences Inc. logo

Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)

ByQuantisnow·Wall Street's wire, on your screen.
SNTI· Senti Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SNTI (Senti Biosciences Inc.) and more on Quantisnow.